Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson’s disease

References

• TannerCMAstonDAEpidemiology of Parkinson’s disease and akinetic syndromesCurr Opin Neurol20001342710970060
   PubMedGoogle Scholar
• MiyasakiJMMartinWSuchowerskyOPractice parameter: initiation of treatment for parkinson’s disease: an evidence-based review Report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology2002581111711781398
   PubMed Web of Science ®Google Scholar
• PahwaRFactorSALyonsKEPractice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology200666798399516606909
   PubMed Web of Science ®Google Scholar
• HoffmanBBLefkowitzRJCatecholamines, sympoathomimetic drugs, and adrenergic receptor antagonistsHardmanJGLimbirdLEGoodman GilmanAGoodman and Gilman’s The Pharmacological Basis of TherapeuticsNew YorkMcGraw-Hill1996199248
   Google Scholar
• RajputAZesiewiczTAHauserRAMonoamine oxidase inhibitorsFactorSAWeinerWJParkinson’s Disease: Diagnosis and Clinical ManagementNew YorkDemos Medical Publishing2008499513
   Google Scholar
• FowlerCJTiptonKFOn the substrate specificities of the two forms of monoamine oxidaseJ Pharm Pharmacol19843621111156143794
   PubMed Web of Science ®Google Scholar
• RohatagiSBar rettJSdeWittKEMoralesRJIntegrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administrationBiopharm Drug Dispos19971875675849330778
   PubMed Web of Science ®Google Scholar
• DollerHJConnorJDChanges in neostriatal dopamine concentrations in response to levodopa infusionsJ Neurochem1980345126412697373307
   PubMed Web of Science ®Google Scholar
• LewittPAMAO-B inhibitor know-how: back to the pharmNeurology200972151352135719365057
   PubMed Web of Science ®Google Scholar
• GoetzCGStebbinsGTChmuraTATeaching tape for the motor section of the unified Parkinson’s Disease Rating ScaleMov Disord19951032632667544438
   PubMed Web of Science ®Google Scholar
• ShulmanLMGruber-BaldiniALAndersonKEThe clinically important difference on the unified Parkinson’s Disease Rating ScaleArch Neurol2010671647020065131
   PubMedGoogle Scholar
• HauserRAFriedlanderJZesiewiczTAA home diary to assess functional status in patients with Parkinson’s disease with motor fluctuations and dyskinesiaClin Neuropharmacol2000232758110803796
   PubMed Web of Science ®Google Scholar
• Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. The Parkinson Study GroupN Engl J Med199332831761838417384
   PubMed Web of Science ®Google Scholar
• PalhagenSHeinonenEHHagglundJSelegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study GroupNeurology19985125205259710028
   PubMed Web of Science ®Google Scholar
• TetrudJWLangstonJWThe effect of deprenyl (selegiline) on the natural history of Parkinson’s diseaseScience198924549175195222502843
   PubMed Web of Science ®Google Scholar
• MyllylaVVSotaniemiKAVuorinenJAHeinonenEHSelegiline in de novo parkinsonian patients: The Finnish StudyMov Disord19938Suppl 1S41S448302307
   PubMed Web of Science ®Google Scholar
• ClarkeAA new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibitionJ Neural Transm200311011125714628190
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupA controlled trial of rasagiline in early Parkinson disease: the TEMPO studyArch Neurol200259121937194312470183
   PubMed Web of Science ®Google Scholar
• OlanowCWRascolOHauserRA double-blind, delayed-start trial of rasagiline in Parkinson’s diseaseN Engl J Med2009361131268127819776408
   PubMed Web of Science ®Google Scholar
• OlanowCWRascolOHauserRA double-blind, delayed-start trial of rasagiline in Parkinson’s diseaseN Engl J Med2009361131268127819776408
   PubMed Web of Science ®Google Scholar
• HeinonenEHRinneUKSelegiline in the treatment of Parkinson’s diseaseActa Neurol Scand Suppl19891261031112515715
   PubMedGoogle Scholar
• LeesAJCurrent controversies in the use of selegiline hydrochlorideJ Neural Transm Suppl1987251571623123602
   PubMedGoogle Scholar
• GolbeLILiebermanANMuenterMDDeprenyl in the treatment of symptom fluctuations in advanced Parkinson’s diseaseClin Neuropharmacol198811145553127050
   PubMed Web of Science ®Google Scholar
• WatersCHSethiKDHauserRAZydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled studyMov Disord200419442643215077240
   PubMed Web of Science ®Google Scholar
• ShoulsonIOakesDFahnSImpact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the Deprenyl and Tocopherol Anti-oxidative Therapy of Parkinsonism TrialAnn Neurol200251560461212112107
   PubMed Web of Science ®Google Scholar
• LiebermanANGopinathanGNeophytidesAFooSHDeprenyl versus placebo in Parkinson disease: a double-blind studyNY State J Med19878712646649
   Google Scholar
• Parkinson Study GroupA randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO studyArch Neurol200562224124815710852
   PubMed Web of Science ®Google Scholar
• RascolOBrooksDJMelamedERasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting Effect in Adjunct Therapy with Rasagiline Given Once Daily Study): a randomised, double-blind, parallel-group trialLancet2005365946394795415766996
   PubMed Web of Science ®Google Scholar
• ShulmanLMGruber-BaldiniALAndersonKEThe evolution of disability in Parkinson diseaseMov Disord200823679079618361474
   PubMed Web of Science ®Google Scholar
• SchawabRSEnglandACJrParkinson’s disease: rehabilitation aspectsRehabil Lit19612232623613909632
   PubMedGoogle Scholar
• HeinonenEHRinneUKTuominenJSelegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatmentActa Neurol Scand Suppl19891261131182515716
   PubMedGoogle Scholar
• LarsenJPBoasJThe effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: An interim analysis of a Norwegian–Danish 5-year study. Norwegian–Danish Study GroupMov Disord19971221751829087975
   PubMed Web of Science ®Google Scholar
• WebsterDDCritical analysis of the disability in Parkinson’s diseaseMod Treat1968522572825655944
   PubMedGoogle Scholar
• CanterCde la TorreRMierMA method of evaluating disabilities in patients with Parkinson’s diseaseJ Nerv Ment Dis196113314314713876261
   PubMed Web of Science ®Google Scholar
• LeesAJComparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease Parkinson’s Disease Research Group of the United KingdomBMJ19953117020160216078555803
   PubMed Web of Science ®Google Scholar
• KluckRMBossy-WetzelEGreenDRNewmeyerDDThe release of cytochrome C from mitochondria: a primary site for bcl-2 regulation of apoptosisScience19972755303113211369027315
   PubMed Web of Science ®Google Scholar
• ShahaniNGourie-DeviMNaliniA(-)-Deprenyl alleviates the degenerative changes induced in the neonatal rat spinal cord by CSF from amyotrophic lateral sclerosis patientsAmyotroph Lateral Scler Other Motor Neuron Disord20045317217915512906
   PubMed Web of Science ®Google Scholar
• CarrilloMCMinamiCKitaniKEnhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the ratLife Sci200067557758510993123
   PubMed Web of Science ®Google Scholar
• MaruyamaWYamamotoTKitaniKMechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagilineMech Ageing Dev200011623181191
   Web of Science ®Google Scholar
• TakahataKShimazuSKatsukiHEffects of selegiline on antioxidant systems in the nigrostriatum in ratJ Neural Transm2006113215115815959853
   PubMed Web of Science ®Google Scholar
• FinbergJPTakeshimaTJohnstonJMCommissiongJWIncreased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitorNeuroreport1998947037079559942
   PubMed Web of Science ®Google Scholar
• MaruyamaWAkaoYCarrilloMCNeuroprotection by propargylamines in Parkinson’s disease: suppression of apoptosis and induction of prosurvival genesNeurotoxicol Teratol200224567568212200198
   PubMed Web of Science ®Google Scholar
• SharmaSKCarlsonECEbadiMNeuroprotective actions of selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neuronsJ Neurocytol200332432934314724376
   PubMedGoogle Scholar
• EbadiMSharmaSShavaliSThe multiple actions of selegilineProc West Pharmacol Soc200245394112434521
   PubMedGoogle Scholar
• BlandiniFNeuroprotection by rasagiline: a new therapeutic approach to Parkinson’s disease?CNS Drug Rev200511218319416007239
   PubMedGoogle Scholar
• KupschASautterJGotzMEMPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegilineJ Neural Transm20011088–9985100911716151
   PubMed Web of Science ®Google Scholar
• BlandiniFArmenteroMTFancelluRNeuroprotective effect of rasagiline in a rodent model of Parkinson’s diseaseExp Neurol2004187245545915144871
   PubMed Web of Science ®Google Scholar
• SimonLSzilagyiGBoriZ(-)-D-deprenyl attenuates apoptosis in experimental brain ischaemiaEur J Pharmacol200143023235241
   Web of Science ®Google Scholar
• SpeiserZMaykAEliashSCohenSStudies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the ratJ Neural Transm199910678593606
   Web of Science ®Google Scholar
• HolfordNHChanPLNuttJGParkinson Study GroupDisease progression and pharmacodynamics in Parkinson disease: evidence for functional protection with levodopa and other treatmentsJ Pharmacokinet Pharmacodyn200633328131116625427
   PubMed Web of Science ®Google Scholar
• D’AgostinoRBThe delayed-start study designN Engl J Med2009361131304130619776413
   PubMed Web of Science ®Google Scholar
• OlanowCWRascolOThe delayed-start study in Parkinson disease: can’t satisfy everyoneNeurology201074141149115020368635
   PubMed Web of Science ®Google Scholar
• AhlskogJEUittiRJRasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?Neurology201074141143114820368634
   PubMed Web of Science ®Google Scholar
• AhlskogJEUittiRJReply to Drs. Olanow and RascolNeurology20107414115120368636
   PubMed Web of Science ®Google Scholar
• SampaioCFerreiraJJParkinson disease: ADAGIO trial hints that rasagiline slows disease progressionNat Rev Neurol20106312612820212427
   PubMed Web of Science ®Google Scholar
• MehtaSHMorganJCSethiKDDoes rasagiline have a disease-modifying effect on Parkinson’s disease?Curr Neurol Neurosci Rep201010641341620711692
   PubMed Web of Science ®Google Scholar
• HeinonenEHSafety of selegiline (deprenyl) in the treatment of Parkinsons diseaseDrug Safety1998191119673855
   PubMed Web of Science ®Google Scholar
• MyllylaVVSotaniemiKMaki-IkolaORole of selegiline in combination therapy of Parkinson’s diseaseNeurology199612476 Suppl 3S200S2098959989
   PubMed Web of Science ®Google Scholar
• ElizanTSMorosDAYahrMDEarly combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson’s disease: experience in 26 patients receiving combined therapy for 26 monthsArch Neurol199148131341898848
   PubMedGoogle Scholar
• GolbeLILong-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson’s diseaseNeurology1989398110911112503769
   PubMed Web of Science ®Google Scholar
• WatersCHSide effects of selegiline (eldepryl)J Geriatr Psychiatry Neurol19925131341571071
   PubMedGoogle Scholar
• ChurchyardAMathiasCJBoonkongchuenPLeesAJAutonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s diseaseJ Neurol Neurosurg Psychiatry19976322282349285463
   PubMed Web of Science ®Google Scholar
• GoetzCGSchwidSREberlySWParkinson Study Group TEMPO and PRESTO InvestigatorsSafety of rasagiline in elderly patients with Parkinson diseaseNeurology20066691427142916682679
   PubMed Web of Science ®Google Scholar
• Leegwater-KimJBortanEThe role of rasagiline in the treatment of Parkinson’s diseaseClin Interv Aging2010514915620517484
   PubMed Web of Science ®Google Scholar
• MarleyEBlackwellBInteractions of monoamine oxidase inhibitors, amines, and foodstuffsAdv Pharmacol Chemother197081853494947578
   PubMedGoogle Scholar
• ElsworthJDGloverVReynoldsGPDeprenyl administration in man: a selective monoamine oxidase B inhibitor without the ’cheese effect’Psychopharmacology (Berl)1978571333896466
   PubMed Web of Science ®Google Scholar
• SchulzRTyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegilineClin Pharmacol Ther19894655282510962
   PubMed Web of Science ®Google Scholar
• HeinonenEHLammintaustaRA review of the pharmacology of selegilineActa Neurol Scand Suppl199113644591686954
   PubMedGoogle Scholar
• GorenTClinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagilineJ Clin Pharmacol201050121420142820445015
   PubMed Web of Science ®Google Scholar
• deMarcaidaJAEffects of tyramine administration in Parkinson’s disease patients treated with selective MAO-B inhibitor rasagilineMov Disord20062110171616856145
   PubMed Web of Science ®Google Scholar
• SternbachHThe serotonin syndromeAm J Psychiatry199114867057132035713
   PubMed Web of Science ®Google Scholar
• RadomskiJWDursunSMReveleyMAKutcherSPAn exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteriaMed Hypotheses200055321822410985912
   PubMed Web of Science ®Google Scholar
• OatesJASjoerdsmaANeurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitorNeurology1960101076107813730138
   PubMed Web of Science ®Google Scholar
• MasonPJMorrisVABalcezakTJSerotonin syndrome presentation of 2 cases and review of the literatureMedicine (Baltimore)200079420120910941349
   PubMed Web of Science ®Google Scholar
• WatersCHFluoxetine and selegiline: lack of significant interactionCan J Neurol Sci19942132592618000982
   PubMed Web of Science ®Google Scholar
• FeighnerJPBoyerWFTylerDLNeborskyRJAdverse consequences of fluoxetine-MAOI combination therapyJ Clin Psychiatry19905162222252347858
   PubMed Web of Science ®Google Scholar
• RichardIHKurlanRTannerCSerotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Parkinson Study GroupNeurology1997484107010779109902
   PubMed Web of Science ®Google Scholar
• HilliJKorhonenTLaineKLack of clinically significant interactions between concomitantly administered rasagiline and escitalopramProg Neuropsychopharmacol Biol Psychiatry20093381526153219733607
   PubMed Web of Science ®Google Scholar
• EvansAHKatzenschlagerRPaviourDPunding in Parkinson’s disease: its relation to the dopamine dysregulation syndromeMov Disord200419439740515077237
   PubMed Web of Science ®Google Scholar
• EvansAHLawrenceADCresswellSACompulsive use of dopaminergic drug therapy in Parkinson’s disease: reward and anti-rewardMov Disord201025786787620461804
   PubMed Web of Science ®Google Scholar
• EvansAHLawrenceADPottsJFactors influencing susceptibility to compulsive dopaminergic drug use in Parkinson diseaseNeurology200565101570157416301483
   PubMed Web of Science ®Google Scholar
• GiovannoniGO’SullivanJDTurnerKHedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapiesJ Neurol Neurosurg Psychiatry200068442342810727476
   PubMed Web of Science ®Google Scholar
• LawrenceADEvansAHLeesAJCompulsive use of dopamine replacement therapy in Parkinson’s disease: reward systems gone awry?Lancet Neurol200321059560414505581
   PubMed Web of Science ®Google Scholar
• GrossetDEuropean PD Therapy Compliance Study GroupTherapy adherence issues in Parkinson’s diseaseJ Neurol Sci201028912115118
   Web of Science ®Google Scholar
• GrossetDAntoniniACanesiMAdherence to antiparkinson medication in a multicenter european studyMov Disord200924682683219191340
   PubMed Web of Science ®Google Scholar
• OlanowCWObesoJAStocchiFDrug insight: continuous dopaminergic stimulation in the treatment of Parkinson’s diseaseNat Clin Pract Neurol20062738239216932589
   PubMedGoogle Scholar
• StocchiFVaccaLRuggieriSOlanowCWIntermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic studyArch Neurol200562690591015956161
   PubMedGoogle Scholar
• GrossetDAntoniniACanesiMAdherence to antiparkinson medication in a multicenter European studyMov Disord200924682683219191340
   PubMed Web of Science ®Google Scholar
• ZesiewiczTASullivanKLArnulfIPractice parameter: treatment of nonmotor symptoms of Parkinson disease Report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology2010741192493120231670
   PubMed Web of Science ®Google Scholar
• Gruber-BaldiniALYeJAndersonKEShulmanLMEffects of optimism/pessimism and locus of control on disability and quality of life in Parkinson’s diseaseParkinsonism Relat Disord200915966566919362510
   PubMed Web of Science ®Google Scholar
• BrysonHMMilneRJChrispPSelegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson’s diseasePharmacoeconomics19922211813610146952
   PubMedGoogle Scholar
• LyonsKEFriedmanJHHermanowiczNOrally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effectsClin Neuropharmacol201033151019855267
   PubMed Web of Science ®Google Scholar
• BiglanKMSchwidSEberlySRasagiline improves quality of life in patients with early Parkinson’s diseaseMov Disord200621561662316450340
   PubMed Web of Science ®Google Scholar
• JostWHKlasserMReichmannHRasagiline in daily clinical use: results of a treatment study of Parkinson patients with a combination treatmentFortschr Neurol Psychiatr2008761059459918833504
   PubMed Web of Science ®Google Scholar